Bronchial Diseases Clinical Trial
Official title:
Patient Reported Outcome and Experience Measures for Bronchoscopic Procedures
'Patient-reported outcomes' (PROMS) and 'patient-reported experiences' (PREMS) are increasingly important parameters in evaluating and adjusting clinical procedures and strategies in healthcare. Validated disease-specific PROMS related to bronchoscopic procedures are not available and examples in the medical literature are very scarce.
The potential usefulness of PROM/PREMS is multiple: 1. Quality improvement within the current clinical care structure 2. Monitoring the health status of the population 3. Contribution to decision-making regarding financing of care 4. Increase employee and patient involvement in clinical care pathways 5. Rationalize the deployment of medical personnel and resources 6. Integration of data in electronic patient files and registers ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03688074 -
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
|
Phase 2 | |
| Recruiting |
NCT04319705 -
Anti-viral Effects of Azithromycin in Patients With Asthma and COPD
|
Phase 4 | |
| Completed |
NCT02162576 -
Asthma Data Innovation Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT04222972 -
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
| Completed |
NCT00932802 -
Greatest International Antiinfective Trial With Avelox
|
N/A | |
| Recruiting |
NCT06272370 -
Individualizing Treatment for Asthma in Primary Care
|
Phase 4 | |
| Completed |
NCT00989521 -
Effect of PUR003 on Asthma
|
Phase 1 | |
| Enrolling by invitation |
NCT04697446 -
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
|
||
| Completed |
NCT01264055 -
Cross-sectional Characterization of Idiopathic Bronchiectasis
|
||
| Withdrawn |
NCT00830427 -
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
|
Phase 2 |